Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis

Study Identifier
2001-022
CT.gov Identifier
NCT00053547
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Secondary Hyperparathyroidism
    • Study Drug
  • paricalcitol injection
    • Phase
    CSR.ORG
    Sex
    Female & Male
    Age
    2 - 20 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    Subjects ages 2-20 with ESRD on hemodialysis with Secondary hyperparathyroidism

    Protocol Summary

    The purpose of this study is to see if Zemplar, a vitamin D medication, safely and

    effectively decreases parathyroid hormone in children ages 2-20 with End Stage Renal Disease.

    Study Locations

    Location
    Status
    Location
    Stanford University Medical Center
    Stanford, California, United States, 94305
    Status
    Not applicable
    Location
    Miami Children's Hospital
    Miami, Florida, United States
    Status
    Not applicable
    Location
    The Children's Hospital of Buffalo
    Buffalo, New York, United States
    Status
    Not applicable
    Location
    Texas Children's Hospital
    Houston, Texas, United States
    Status
    Not applicable
    Location
    University of Texas at Houston
    Houston, Texas, United States
    Status
    Not applicable
    Location
    Medical College of Wisconsin
    Milwaukee, Wisconsin, United States
    Status
    Not applicable